D
Denali Therapeutics Tech Stack
Blood-brain barrier drug delivery platform for neurodegenerative diseases
Denali is a public biotech company developing therapeutics that cross the blood-brain barrier using a proprietary TransportVehicle™ platform, focused on neurodegenerative and lysosomal storage diseases. The hiring mix—heavily skewed toward manufacturing (12 roles) and leadership (9 directors, 2 VPs)—paired with active projects around tech transfer, site buildout, and GMP compliance signals a company scaling manufacturing operations and regulatory infrastructure to move candidates toward clinical and commercial stages.
Tech Stack 15 technologies
Core StackWorkday Smartsheet qPCR GraphPad Prism Excel HPLC LC-MS SDS-PAGE Microsoft Office UPLC LIMS Word SharePoint Veeva RIM LabWare LIMS
What Denali Therapeutics Is Building
◆Challenges
- Ensuring gmp compliance
- Regulatory filing complexity
- Maintaining audit readiness
- Global regulatory strategy
- Missed timelines
- Operational performance improvement
- Late-stage manufacturing challenges
- Maintaining compliance systems
- Supporting scale-up projects
- Onboarding new equipment
▲Active Projects
- Tech transfer
- Method lifecycle management
- Potency assay development for large molecule biotherapeutics
- International regulatory strategy development
- Site upgrades and buildout
- Global regulatory process and tool development
- Bioassay qualification for product release and stability testing
- Bioprocess and formulation support
- Site-wide metrology and calibration program
- Activity and potency characterization for antibodies and gene therapies
Hiring Activity
35 roles · 15 in 30d
Department
Seniority
Company intelligence
